Glezisim 10 mg/10 mg tablety Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

glezisim 10 mg/10 mg tablety

glenmark pharmaceuticals s.r.o., Česká republika - simvastatín a ezetimib - 31 - hypolipidaemica

Evotaz Európska únia - slovenčina - EMA (European Medicines Agency)

evotaz

bristol-myers squibb pharma eeig - cobicistat, atazanavir - hiv infekcie - antivirotiká na systémové použitie - evotaz is indicated in combination with other antiretroviral medicinal products for the treatment of hiv-1 infected adults and adolescents (aged 12 years and older weighing at least 35 kg) without known mutations associated with resistance to atazanavir (see sections 4. 4 a 5.

Rezolsta Európska únia - slovenčina - EMA (European Medicines Agency)

rezolsta

janssen-cilag international n.v. - darunavir, cobicistat - hiv infekcie - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - rezolsta je indikovaný v kombinácii s inými antiretrovírusovými liekmi na liečbu infekcie vírusom ľudskej imunodeficiencie 1 (hiv 1) u dospelých vo veku 18 rokov a starších. genotypic testovanie by sa malo riadiť použitie rezolsta.

Tybost Európska únia - slovenčina - EMA (European Medicines Agency)

tybost

gilead sciences ireland uc - cobicistat - hiv infekcie - antivirotiká na systémové použitie - tybost is indicated as a pharmacokinetic enhancer of atazanavir 300 mg once daily or darunavir 800 mg once daily as part of antiretroviral combination therapy in human immunodeficiency virus-1 (hiv-1) infected adults and adolescents aged 12 years and older:weighing at least 35 kg co‑administered with atazanavir orweighing at least 40 kg co‑administered with darunavir.

Symtuza Európska únia - slovenčina - EMA (European Medicines Agency)

symtuza

janssen-cilag international nv - darunavir, cobicistat, emtricitabine, tenofovir alafenamide - hiv infekcie - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - symtuza je indikovaný na liečbu vírusu ľudskej imunodeficiencie typu 1 infekcie (hiv‑1) u dospelých a dospievajúcich (vo veku 12 rokov a starších s telesná hmotnosť aspoň 40 kg). genotypic testing should guide the use of symtuza.

Sandimmun 50 mg/ml Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

sandimmun 50 mg/ml

novartis slovakia s.r.o., slovensko - cyklosporín - 59 - immunopraeparata

Livtencity Európska únia - slovenčina - EMA (European Medicines Agency)

livtencity

takeda pharmaceuticals international ag ireland branch - maribavir - cytomegalovírusové infekcie - antivirotiká na systémové použitie - livtencity is indicated for the treatment of cytomegalovirus (cmv) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (hsct) or solid organ transplant (sot). je treba vziať do úvahy oficiálne usmernenie o vhodnom používaní protivírusové agentov.

Ezetimib/simvastatín Teva 10 mg/40 mg Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

ezetimib/simvastatín teva 10 mg/40 mg

teva pharmaceuticals slovakia s.r.o., slovensko - simvastatín a ezetimib - 31 - hypolipidaemica

Ezetimib/simvastatín Teva 10 mg/20 mg Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

ezetimib/simvastatín teva 10 mg/20 mg

teva pharmaceuticals slovakia s.r.o., slovensko - simvastatín a ezetimib - 31 - hypolipidaemica

Sunlenca Európska únia - slovenčina - EMA (European Medicines Agency)

sunlenca

gilead sciences ireland unlimited company - lenacapavir sodium - hiv infekcie - antivirotiká na systémové použitie - sunlenca injection, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant hiv 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen (see sections 4. 2 a 5. sunlenca tablet, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant hiv 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen, for oral loading prior to administration of long-acting lenacapavir injection (see sections 4. 2 a 5.